The subject of this publication is the conclusion of discount agreements for the following X-ray contrast media (ATC code according to WHO: V08):

- Lot 1 amidotrizoic acid up to 30 ml

- Lot 2 amidotrizoic acid more than 30 ml

- The 3 Ioxitalaminsäure

- The 4 Iohexol

- The 5 Iopamidol

- The 6 Iopromid

- The 7 Ioversol

- Los 8 Iodixanol

- Lot 9 iomeprole up to 350 mg

- The 10 Iomeprol 400 mg

- The 11 Iobitridol

- Lot 12 Ethyl ester of iodized fatty acids

- Lot 13 Barium sulphate with suspension

- The 14 Gadopentetsäure

- The 15 Gadotersäure

- The 16 Gadoteridol

- The 17 Gadobensäure

- The 18 Gadobutrol

- The 19 Gadoxetsäure

- The 20 Humanalbumin-Mikrosphären

- Los 21 Phospholipid-Mikrosphären

- Lot 22 Sulphur hexafluoride

The contract is concluded (lot-related) within the framework of a so-called open-house model, i.e. a contract is open to all interested pharmaceutical companies/wholesalers/pharmacies within the participation period, provided that they meet and accept the participation requirements. As a result, individual contract negotiations are not conducted and (delivery) exclusivity is not given. It should be noted that the purchase quantity is unknown; Accordingly, minimum purchase quantities are not guaranteed.

Interested parties can download the participation documents via the project room of the German Public Procurement Portal (DTVP). For this purpose, an application for access to the project room is first required. After successful activation by the client, the participation documents can then be accessed. The documents to be submitted result from the documents "Cover letter" and "Explanations of the contractual conditions" deposited in the project room.

Communication, including the transmission of participation documents, takes place electronically via the DTVP procurement portal; Details can be found in the above-mentioned documents. Any information to the contrary in the contract notice is due to technical reasons and does not claim any liability.

The participation documents must be submitted in full by the 15th of each month (receipt deadline). It depends on the access at the AOK PLUS. If the 15th of a month falls on a Saturday, Sunday or nationwide public holiday, the next working day takes the place of such a day. In case of later receipt (after the 15th of a month), the submitted participation documents will be taken into account for the 15th of the following month.

Participation documents can be submitted for the first time until 15 February 2023.

The client reserves the right, in compliance with the principles of transparency and equal treatment, to request the interested companies to submit, complete or correct missing, incomplete or incorrect documents (in particular declarations, information and evidence) (additional demand). The documents shall be submitted on request within a time limit specified in the calendar. If the requested documents are not submitted within the deadline, the request to participate may be excluded or considered only at the next submission deadline.

The discount agreement ends regardless of the date of conclusion of the contract at the latest on 31.03.2025.

The client reserves the right to terminate the open house procedure prematurely (possibly drawn by lots), in particular in the event of the conclusion of exclusive discount agreements; in this case, the discount agreements already concluded shall terminate in accordance with the contractual provisions. Experience has shown that exclusive rebate agreements normally enter into force 8 to 12 months after the publication of the relevant contract notice in the Supplement to the Official Journal of the European Union.

Further information can be found in the participation documents, in particular the document "Explanations of the contractual conditions".

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient amidotrizoic acid up to a maximum of 30 ml amount of contrast agent per divided dosage form (ATC according to WHO: V08AA01) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("open house discount agreement").

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient iomeprol 400 mg iodine/ml (ATC according to WHO: V08AB10) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("Open House Discount Agreement").

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient iobidridol (ATC according to WHO: V08AB11) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("Open House Discount Agreement").

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient ethyl ester of iodized fatty acids (ATC according to WHO: V08AD01) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("Open House Discount Agreement").

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient barium sulfate with suspension agent, liquid DRF (ATC according to WHO: V08BA01) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("Open House Discount Agreement").

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient gadopentetic acid (ATC according to WHO: V08CA01) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("Open House Discount Agreement").

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient gadoteric acid (ATC according to WHO: V08CA02) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("Open House Discount Agreement").

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient gadoteridol (ATC according to WHO: V08CA04) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("Open House Discount Agreement").

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient gadobenic acid (ATC according to WHO: V08CA08) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("Open House Discount Agreement").

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient gadobutrol (ATC according to WHO: V08CA09) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("Open House Discount Agreement").

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient gadoxetic acid (ATC according to WHO: V08CA10) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("Open House Discount Agreement").

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient amidotrizoic acid with more than 30 ml amount of contrast agent per divided dosage form (ATC according to WHO: V08AA01) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("Open House Discount Agreement").

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient human albumin microspheres (ATC according to WHO: V08DA01) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("Open House Discount Agreement").

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient phospholipid microspheres (ATC according to WHO: V08DA04) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("Open House Discount Agreement").

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient sulfur hexafluoride (ATC according to WHO: V08DA05) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("Open House Discount Agreement").

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient ioxitaramine acid (ATC according to WHO: V08AA05) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("Open House Discount Agreement").

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient iohexol (ATC according to WHO: V08AB02) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("Open House Discount Agreement").

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient iopamidol (ATC according to WHO: V08AB04) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("Open House Discount Agreement").

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient iopromide (ATC according to WHO: V08AB05) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("Open House Discount Agreement").

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient ioversol (ATC according to WHO: V08AB07) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("Open House Discount Agreement").

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient iodixanol (ATC according to WHO: V08AB09) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("Open House Discount Agreement").

Conclusion of a non-exclusive discount agreement for contrast agents with the active ingredient iomeprol up to 350 mg iodine/ml (ATC according to WHO: V08AB10) in the period from February 2023 to 31 March 2025 with the possibility of concluding a contract during this period ("Open House Discount Agreement").